C4 Therapeutics climbs after partnership with Pfizer for cancer therapy trial

C4 Therapeutics

01/10/2025 12:50

** Shares of drug developer C4 Therapeutics CCCC.O rise 8% to $2.40 premarket

** Co says it has partnered with Pfizer PFE.N to test a combination therapy for cancer

** CCCC will test its drug cemsidomide with Pfizer's elranatamab in patients with multiple myeloma, a type of blood cancer, who have already received at least one prior treatment

** Under the deal, Pfizer will supply elranatamab, sold under the brand name Elrexfio, at no cost, while C4 Therapeutics will lead and sponsor the early-stage trial, which is expected to begin in Q2 of 2026

** As of last close, stock down 38% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))